A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer
Phase of Trial: Phase II
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Tivantinib (Primary) ; Cetuximab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 24 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.